title: Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2).
authors.affiliation: Duke University Medical Center, Durham, NC, USA.
authors.forename: J
authors.initials: J
authors.lastname: Crawford
authors.forename: D S
authors.initials: DS
authors.lastname: Duch
authors.forename: R J
authors.initials: RJ
authors.lastname: Gralla
authors.forename: B E
authors.initials: BE
authors.lastname: Hillner
authors.forename: P J
authors.initials: PJ
authors.lastname: Hollen
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D003365:Costs and Cost Analysis; D016527:Drug Costs; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D011788:Quality of Life; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents